Zobrazeno 1 - 10
of 424
pro vyhledávání: '"Ragavendra R"'
Autor:
Ankur Sheel, Junu Bae, Ashlee Asada, Gregory A. Otterson, Ragavendra R. Baliga, Kristin L. Koenig
Publikováno v:
Cardio-Oncology, Vol 9, Iss 1, Pp 1-6 (2023)
Abstract Background Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML). While the HMA decitabine, in its intravenous formulati
Externí odkaz:
https://doaj.org/article/8ad7f046ca434399a6659ce354285d41
Autor:
Debabrata Mukherjee, Richard Lange, Steve Bailey, Ragavendra R. Baliga, Michael Blaha, Bozkurt Biykem
Written by clinicians, for clinicians, Cardiovascular Medicine and Surgery offers a comprehensive, authoritative, and multidisciplinary approach to this rapidly evolving field. Covering every area relevant to the daily practice of cardiovascula
Dyslipidemia affects almost half of American adults and is the most prevalent manageable risk factor for atherosclerosis. Lipid disorders often co-occur with other prevalent conditions such as diabetes and kidney disease; they are also often a concer
Autor:
George Bakris, Ragavendra R. Baliga
Over 75 million American adults suffer from hypertension, the leading risk factor for stroke and cardiovascular disease. Individuals who are normotensive at age 55 have a 90% lifetime risk for developing high blood pressure. Despite increased awarene
Autor:
Korada, Sai Krishna C., Mann, James A., Hasan, Ayesha K., Baliga, Ragavendra R., Mokadam, Nahush A., Benza, Raymond L., Vallakati, Ajay
Publikováno v:
In Heart & Lung November-December 2020 49(6):688-691
Autor:
Ragavendra R Baliga, MD
The first HMG-CoA reductase inhibitor (statin) lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin, and simvastatin, have been approved by the FDA. Statins
Publikováno v:
Heart Failure Clinics. 19:xi-xiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edfd42496a21385f377ad431a559ddf5
https://doi.org/10.1016/j.hfc.2023.03.003
https://doi.org/10.1016/j.hfc.2023.03.003
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Heart Failure Clinics. 18:xi-xiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b5f47a8a75a4e49cd77123a73b3be31
https://doi.org/10.1016/j.hfc.2022.07.001
https://doi.org/10.1016/j.hfc.2022.07.001
Autor:
Thanikachalam, Sadagopan, Harivanzan, Vijayakumar, Mahadevan, Murugappapillai V., Murthy, J.S.N., Anbarasi, Chandrasekar, Saravanababu, Chidambaram S., Must, Aviva, Baliga, Ragavendra R., Abraham, William T., Thanikachalam, Mohan
Publikováno v:
In Global Heart December 2015 10(4):281-289